Jun 2026 (Q2 FY26) — Jul 29, 2026
Glaukos Q2 FY26 — Record Sales Driven by iDose TR and Epioxa Launches
Read the full callGlaukos (GKOS) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Glaukos earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 186 | +49.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -9.3 | +9.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -18.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$166.96 +1.29% · +$2.12
Performance +91.5% 1Y
1Y: $87.17 on 17 Oct 2025 → $166.96. High $189.55 (19 Aug 2026), low $74.67 (24 Oct 2025).
- Previous close
- $164.84
- 52-week range
- $74.67 – $189.55
- One year
- +110.09%
Overview
- Symbol
- GKOS
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — Apr 29, 2026
Glaukos Corporation Q1 FY26 — Record Sales Driven by iDose TR and Epioxa Launch
Read the full callEvery analysed call
Glaukos earnings calls (GKOS)
Financials
What the filings say
Net profit, year on year: +7% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 97 | 105 | 107 | 124 | 134 | 143 | 151 | 186 |
| Operating profit | -25 | -29 | -21 | -23 | -16 | -140 | -20 | -17 |
| Operating margin | −25.5% | −27.2% | −19.4% | −18.3% | −12.3% | −97.7% | −13.2% | −9.3% |
| Other income | 3 | -5 | 3 | 3 | 0 | 0 | 1 | -0 |
| Interest | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -21 | -34 | -18 | -19 | -16 | -140 | -19 | -18 |
| Tax rate | −0.8% | 0.3% | −1.8% | −1.3% | −1.5% | 4.4% | −2.5% | −3.7% |
| Net profit | -21 | -34 | -18 | -20 | -16 | -134 | -20 | -18 |
| EPS ($ per share) | -0.39 | — | -0.32 | -0.34 | -0.28 | — | -0.34 | -0.31 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -205 | -190 | -310 | -365 | -464 | -599 | -745 | -933 |
| Total liabilities | 33 | 145 | 338 | 463 | 472 | 479 | 208 | 237 |
| Fixed assets | 19 | 22 | 24 | 69 | 94 | 103 | 98 | 113 |
| Total assets | 207 | 818 | 1,006 | 1,050 | 1,002 | 940 | 975 | 893 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 19 | -0 | -23 | 25 | -33 | -58 | -61 | -15 |
| Cash from investing | -26 | 43 | -205 | -58 | 45 | 14 | 48 | -78 |
| Cash from financing | 22 | -10 | 263 | 39 | 6 | 15 | 92 | 12 |
| Net cash flow | 14 | 33 | 34 | 4 | 16 | -27 | 75 | -80 |
| Capital expenditure | -10 | -5 | -7 | -48 | -30 | -20 | -6 | -8 |
| Free cash flow | 9 | -5 | -30 | -23 | -63 | -78 | -68 | -22 |
GKOS revenue by segment
| Segment | Q2 FY2024 | Q3 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| Development and Commercialization Of Ophthalmic Therapies | — | — | 100% | 100% | 100% | 100% | 100% | 100% | +49.5% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 79% ↑ 7 pt
- Non Us 21% ↓ 7 pt
As GKOS cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
145 filings between Nov 18, 2025 and Oct 5, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$69.31M
61 sales by 8 insiders
67% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 25
- Award — granted as compensation
- 21
- Option exercise — converted options into shares
- 32
- Tax withheld — shares kept back by the company to cover tax
Also filed: 6 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Burns Thomas William | — | $31.63M | Jan 16, 2026 |
| Gilliam Joseph E | — | $17.24M | Aug 11, 2026 |
| Thurman Alex R. | — | $10.18M | Aug 7, 2026 |
| Navratil Tomas | — | $3.87M | Oct 5, 2026 |
| Kliman Gilbert H | — | $2.39M | Aug 19, 2026 |
| Stapley Marc | — | $1.92M | Jan 22, 2026 |
| WEISNER AIMEE S | — | $1.76M | Feb 19, 2026 |
| WEN LEANA | — | $331.7K | Jul 31, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 327 | $53.9K |
| Oct 5, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 312 | $51.7K |
| Oct 5, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 888 | $145.6K |
| Sep 25, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 136 | $20.8K |
| Sep 25, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 1,083 | $167.7K |
| Sep 25, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 167 | $25.3K |
| Sep 25, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 229 | $35.3K |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 191 | $31.7K |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 120 | $20.2K |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 234 | $40.0K |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 4 | $688 |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 460 | $77.0K |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 345 | $56.8K |
| Sep 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 103 | $16.8K |
| Aug 28, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale | 6,091 | $1.10M |
| Aug 28, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale | 10 | $1.8K |
| Aug 28, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale | 7,643 | $1.38M |
| Aug 19, 2026 | Kliman Gilbert H Director | Option exercise | 2,500 | $64.4K |
| Aug 19, 2026 | Kliman Gilbert H Director | Sale | 2,500 | $475.0K |
| Aug 11, 2026 | Gilliam Joseph E PRESIDENT & COO | Sale | 27,963 | $5.00M |
| Aug 11, 2026 | Gilliam Joseph E PRESIDENT & COO | Option exercise | 10,000 | $484.6K |
| Aug 11, 2026 | Gilliam Joseph E PRESIDENT & COO | Option exercise | 10,000 | $484.6K |
| Aug 11, 2026 | Gilliam Joseph E PRESIDENT & COO | Option exercise | 20,000 | $1.10M |
| Aug 11, 2026 | Gilliam Joseph E PRESIDENT & COO | Sale | 32,037 | $5.78M |
| Aug 11, 2026 | Gilliam Joseph E PRESIDENT & COO | Option exercise | 20,000 | $1.10M |
| Aug 7, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 20,000 | $3.60M |
| Aug 7, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 20,000 | $676.2K |
| Jul 31, 2026 | WEN LEANA Director | Sale | 525 | $88.0K |
| Jul 16, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 10,000 | $386.8K |
| Jul 16, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 10,000 | $1.60M |
| Jul 9, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 10,000 | $1.55M |
| Jul 9, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 10,000 | $386.8K |
| Jul 6, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Sale 10b5-1 plan | 10,000 | $1.50M |
| Jul 6, 2026 | Thurman Alex R. SVP & CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 plan | 10,000 | $386.8K |
| Jul 1, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 716 | $99.6K |
| Jun 25, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Tax withheld | 483 | $68.9K |
| Jun 25, 2026 | Gilliam Joseph E PRESIDENT & COO | Tax withheld | 1,056 | $150.6K |
| Jun 25, 2026 | Burns Thomas William CHAIRMAN & CEO | Tax withheld | 4,059 | $578.7K |
| Jun 16, 2026 | Navratil Tomas CHIEF DEVELOPMENT OFFICER | Sale 10b5-1 plan | 1,537 | $200.9K |
| May 28, 2026 | Torres Denice Director | Award | 1,878 | $0 |
| May 28, 2026 | Kliman Gilbert H Director | Award | 1,878 | $0 |
| May 28, 2026 | WEN LEANA Director | Award | 1,878 | $0 |
| May 28, 2026 | WEISNER AIMEE S Director | Award | 1,878 | $0 |
| May 28, 2026 | Stapley Marc Director | Award | 1,878 | $0 |
| May 28, 2026 | Foley Mark J Director | Award | 1,878 | $0 |
| May 28, 2026 | Hoffmeister David F Director | Award | 1,878 | $0 |
| May 26, 2026 | Hoffmeister David F Director | Option exercise | 15,000 | $370.4K |
| May 14, 2026 | Kliman Gilbert H Director | Sale | 5,000 | $703.8K |
| May 14, 2026 | Kliman Gilbert H Director | Option exercise | 5,000 | $123.5K |
| May 11, 2026 | Kliman Gilbert H Director | Option exercise | 5,000 | $123.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for GLAUKOS Corp
Free account. Everything above stays public.
Write why you follow GLAUKOS Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading